![conference banner](/images/conference-banner.jpeg)
Abstract
Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.
Current Pharmaceutical Design
Title:The State of the Problem of Achieving Extremely Low LDL Levels
Volume: 27 Issue: 37
Author(s): Victoria Korneva*, Tatiana Kuznetsova and Ulrich Julius
Affiliation:
- Petrozavodsk State University, Faculty Therapy Department, 185000 Lenin Ave., 33, Petrozavodsk,Russian Federation
Keywords: Low-density lipoprotein CH (LDL-C), PCSK9 inhibitors, statins, diabetes mellitus, immune system, malignant neoplasms, brain function.
Abstract: Patients who have achieved very low low-density lipoprotein CH (LDL-C) levels in clinical trials have shown the lowest cardio-vascular risk. The current clinical guidelines set such a concentration for LDL-C as < 1.4 mmol/L. However, the question of minimum permissible target values of the lipids remains unresolved. A number of experimental and clinical studies showed some unfavorable consequences of low LDL-C levels At the same time, the modern arsenal of lipid lowering drugs allows reducing LDL-C levels to extremely low values. This review presents an analysis of literature about the safety of low lipid spectrum parameters.
Export Options
About this article
Cite this article as:
Korneva Victoria *, Kuznetsova Tatiana and Julius Ulrich , The State of the Problem of Achieving Extremely Low LDL Levels, Current Pharmaceutical Design 2021; 27 (37) . https://dx.doi.org/10.2174/1381612827999210111182030
DOI https://dx.doi.org/10.2174/1381612827999210111182030 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insight into JNK Inhibition-based Strategy for the Treatment of
Alzheimer's Disease
Current Enzyme Inhibition Dorsal Stream Dysfunction in Children. A Review and an Approach to Diagnosis and Management
Current Pediatric Reviews Multiple Faceted Roles of Cocaine in Potentiation of HAND
Current HIV Research Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Crosstalk Between Calpain and Calcineurin in Excitotoxic Neurodegeneration; Therapeutic Targets for the Treatment of Excitotoxic Neurodegeneration
Current Medicinal Chemistry - Central Nervous System Agents A Nanotechnological Approach to the Management of Alzheimer Disease and Type 2 Diabetes
CNS & Neurological Disorders - Drug Targets Nanoparticle-Based Gene Therapy Intervention for Stroke Treatment: A Systematic Review
Current Gene Therapy Innovative Therapeutic Potential of Cannabinoid Receptors as Targets in Alzheimer’s Disease and Less Well-Known Diseases
Current Medicinal Chemistry Hypoglycaemia and Cardiovascular Disease Risk in Patients with Diabetes
Current Pharmaceutical Design Liver X Receptor-Mediated Gene Regulation and Cholesterol Homeostasis in Brain: Relevance to Alzheimers Disease Therapeutics
Current Alzheimer Research The Role of Advanced Technologies Supplemented with Traditional Methods in Pharmacovigilance Sciences
Recent Patents on Biotechnology Small Molecule TGF-beta Mimetics as Potential Neuroprotective Factors
Current Alzheimer Research Ameliorative Effects of Baicalein on an Amyloid-β Induced Alzheimer's Disease Rat Model: A Proteomics Study
Current Alzheimer Research The Role of Nicotinamide Phosphoribosyltransferase in Cerebral Ischemia
Current Topics in Medicinal Chemistry Production of Reactive Oxygen Species from Aggregating Proteins Implicated in Alzheimers Disease, Parkinsons Disease and Other Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Inducible Nitric Oxide Synthase as a Possible Target in Hypertension
Current Drug Targets Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy
Current Alzheimer Research Tolfenamic Acid Interrupts the De Novo Synthesis of the β-Amyloid Precursor Protein and Lowers Amyloid Beta Via a Transcriptional Pathway
Current Alzheimer Research Glia as a Turning Point in the Therapeutic Strategy of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Unmet Needs in Schizophrenia
CNS & Neurological Disorders - Drug Targets